Good afternoon, everyone, and welcome to the Beyond Air financial results call for the quarter ended September 30, 2026. At this time, participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. Now, I would like to turn the call over to Corey Davis, LifeSci Advisors. Please go ahead.
Thank you, operator. Good afternoon, everyone, and thank you for joining us. Earlier today, we issued a press release announcing the operational highlights and financial results for Beyond Air's quarter ended September 30, 2026. A copy of this press release can be found on our website, beyondair.net, under the News and Events section. Before we begin, I'd like to remind everyone that we will be making comments and various remarks about future expectations, plans, and prospects, which constitute forward-looking statements for purposes of the Safe Harbor provisions under the Private Securities Litigation Reform Act of 1995. Beyond Air cautions that these forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those indicated.
We encourage everyone to review the company's filings with the Securities and Exchange Commission, including, without limitation, the company's most recent Form 10-Q and Form 10-K, which identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements. Additionally, this conference call is being recorded and will be available for audio rebroadcast on our website, beyondair.net. Furthermore, the content of this conference call contains time-sensitive information that is accurate only as of the date of the live broadcast, November 11, 2026. Beyond Air undertakes no obligation to revise or update any statements to reflect events or circumstances after the date of this call. With that, I'll turn it over to Robert Goodman, Chief Executive Officer of Beyond Air. Bob, go ahead. The floor is yours.
Thanks, Corey, and good afternoon, everyone. I'm pleased to speak with you today and provide an update on what has been a productive and meaningful period for Beyond Air. With me today is Dan Moorhead, our Chief Financial Officer. I'll begin with an update on our recent activities and commercial execution for LungFit PH before turning the call over to Dan to discuss our financial results for the quarter ended September 30, 2026. We'll then open the call for questions. Throughout the third quarter, we continued to focus on positioning the company for its next phase of growth. As we prepare for the planned commercial launch of our second-generation LungFit PH system, pending FDA approval, our priorities remain focused on expanding market penetration, deepening relationships with hospitals and health systems, and growing our commercial pipeline while building on the momentum of our first-generation LungFit PH system.
These efforts contributed to record quarterly revenue of $2.3 million in the September quarter, up approximately 28% year-over-year and 31% from the June quarter. We achieved this growth while maintaining financial discipline and prioritizing resources to support commercial execution and preparations for the potential launch of second-generation LungFit PH. Underlying these results is the progress we are making in expanding market penetration and converting hospital interest into signed customer agreements that support recurring revenue over multiple years. Our in-house sales team is building these relationships supported by national GPO agreements that broaden our reach across hospitals and hospital systems. Our U.S. commercial pipeline is expanding, reflecting accelerated demand for our first-generation system and strong receptivity to our technology and operational efficiencies it offers.
We are especially pleased with the pace of new account wins and the rate of renewals, which speak to the acceptance of our innovative technology and delivery of iNO, resulting in exceptional customer satisfaction, which gives us a foundation to build on as we prepare for the potential launch of the second-generation LungFit PH. International distribution is another important opportunity for growth. We have partnerships in place covering more than 40 countries, and international sales during the quarter were one of the highest to date. Looking ahead, pending FDA approval, we believe our second-generation system has the potential to substantially expand our market opportunity and accelerate growth. The system is smaller, has reduced weight, simplified operation, longer service intervals, and expanded operational flexibility. Our PMA supplement seeks expanded FDA labeling that would permit use during patient transport by air and ground.
Turning to the regulatory process, our PMA supplement for the second-generation LungFit PH remains under FDA review. We remain encouraged by the progress we are making toward completing the remaining steps in the review process. We expect to complete our audit readiness process in mid-December. The system would then remain subject to FDA inspections and final approval. The timing and outcome of these steps remain subject to the FDA's review. We are excited to be at these final steps of the process. As I mentioned a minute ago, the second-generation LungFit adds transport capability. This is important as it will enable us to serve as a single-source nitric oxide provider across routine care and patient transport, which is the current standard across most U.S. hospital systems. This will strengthen our competitive position and support broader adoption of our cylinder-free technology.
Turning to another development program within our LungFit platform, LungFit GO received FDA Breakthrough Device Designation during the quarter for the treatment of nontuberculous mycobacterial pulmonary disease, or NTM PD. We believe this designation underscores the significant unmet need to NTM PD and builds upon clinical data generated with LungFit GO in this patient population. While we are encouraged by this designation, we do not currently plan to allocate resources to further development of LungFit GO in 2027. Our focus remains on commercial execution for LungFit PH and preparations for the launch of our second-generation system, pending FDA approval. Let me now provide a brief update on our two indirect subsidiaries focused on development programs outside of our core LungFit business. During the September quarter, we entered into a definitive agreement under which UNIVO Pharmaceutical Industries would acquire our controlling interest in NeuroNOS Israel.
The transaction is intended to provide NeuroNOS with dedicated resources, funding, and strategic focus to advance its development programs. In terms of Beyond Cancer, we are evaluating potential development partnerships and other strategic arrangements to support continued advancements of its pipeline while maintaining Beyond Air's focus and resource allocation on the commercialization of LungFit PH. Before turning the call over to Dan, I want to emphasize how encouraged we are by the progress we are making with the current LungFit PH offering and the foundation we are strengthening for the potential launch of our second-generation system, pending FDA approval. With this progress, we are reaffirming our revenue guidance of $8 million for calendar year 2026, which excludes revenue from the second-generation system. We are also reaffirming our revenue guidance of $16 million-$18 million for calendar year 2027, which includes anticipated revenue from the second-generation system, pending FDA approval.
With that, I will turn the call over to Dan for a review of our financial results. Dan?
Thanks, Bob, and good afternoon, everyone. Let me take this time to walk through our financial results for the quarter ended September 30th, 2026. Revenue for the quarter was $2.3 million compared with $1.8 million for the same period last year. This represents growth of approximately 28% year-over-year and 31% from the June 2026 quarter. Gross margin for the quarter was approximately 8% compared with negative 16% for the same period last year. Gross profit was $200,000 compared with a gross loss of $300,000 in the prior year quarter. Research and development expenses were $1.6 million compared with $2.5 million for the same period last year. The decrease was primarily attributed to lower costs related to the second-generation LungFit PH, as the majority of the development is complete.
Selling, general, and administrative expenses were $4.6 million compared with $4.9 million for the same period last year. The decrease was attributed primarily to lower stock-based compensation costs, partially offset by increased salaries in our sales organization as we build out our commercial team. Other expense for the three months ended September 30th, 2026, was $2.2 million as compared to other expense of $600,000 for the three months ended September 30th, 2025. The increase in expense was attributed primarily to an increase in interest expense and a charge for scrap materials.
Net loss attributed to common stockholders of Beyond Air for the three months ended September 30, 2026, was $7.8 million, or a loss of $3.76 per basic and diluted share, compared with a net loss of $7.9 million, or a loss of $24.98 per basic and diluted share for the three months ended September 30, 2025. As of September 30, 2026, we reported cash equivalents, restricted cash, and marketable securities of $18.5 million, which includes $2.7 million of cash held by NeuroNOS, which is shown within current assets held for sale on the balance sheet, and also includes $700,000 held by Beyond Cancer. This total also includes $4.8 million of restricted cash. As a reminder, we are transitioning our fiscal year end from March 31 to December 31, effective December 31, 2026.
We expect to report results for the nine-month transition period ending December 31, 2026, on a Form 10-K/T. The revenue guidance Bob discussed is on a calendar year basis. With that, we will now open the call for questions.
Thank you. At this time, we will begin with the question-and-answer session. If you would like to ask a question, please press star one on your telephone keypad. A confirmation tone will indicate that your line is in the question queue. You may press star two if you would like to remove your question from the queue. For participants using speaker equipment, it may be necessary to pick up your handset before pressing the star keys. One moment, please, while we poll for questions . Your first question comes from Yale Jen with Laidlaw & Company. Please state your question.
Great. Thanks for taking the questions. Just two. The first one is that in terms of the FDA review, given that they are going to undergo, suppose you will finish the audit readiness by mid-December, was there any other things that the FDA may look for, or simply just an inspection and then they will make decisions and have a follow-up?
Yeah, it's pretty much just that, Yale. The audit will follow right after we announce our readiness, and as you mentioned, in the middle of December. Nothing that we know of that would be in addition to that. So just a standard audit and feedback.
Okay. Just giving the time and giving the holidays to come, presumably, would that be the best scenario, FDA make hopefully a positive decision, maybe in the first quarter, maybe even in the early first quarter of next year?
Yeah. I mean, that's up to the FDA, as you know, right?
Sure.
Yeah, we're expecting to have a quick response. We've been communicating with them directly with all of our paperwork, couple of questions back and forth. We've satisfied those questions. So we're in great shape there. It's now just the audit part. The good news is the audit, it's a quick audit. Used to be a up to five-day period, but because a lot of it is done via paperwork back and forth for a couple of days, the actual audit's only like a day and a half long. Once that happens, we expect to hear back from them within a few weeks, and then there's just the signature process. So yeah, to your point and your timeline, that's right around where we're pointing at.
Okay. Maybe lastly, your $16 million-$18 million guidance for next year, presumably it is based on this assumption, or do you anticipate any possible sort of push out, and if that happens, would that impact on the guidance? Thanks.
Yeah, no. We are sticking with our $16 million-$18 million, and that includes Gen 2 only in the second, third, and fourth quarter. We do not have in our guidance Gen 2 revenue in that first quarter. We are not expecting to push anything out. In fact, our pipeline has grown really, really dramatically over the last couple of quarters. We have had a really nice increase with our Gen 1 pipeline as well as our new wins there. We have been planning on that, so that is where our coverage has been along the way. No, and we are not expecting to be pushing anything out, at least at this point, of course. Yeah.
You basically built up some cushion in your guidance?
Yeah, we built that just to. As we mentioned that a few months ago, we did not want to expect revenue on day one, Q1, but we know the pipeline will be able to still from one quarter, Q4 to Q1, with our real strong Gen 1. We have Gen 2 coming in, like I said, Q2, 3, and 4.
Okay, great. Thanks a lot. I'll get back to the queue.
Yeah, you got it.
Your next question comes from Frank Takkinen with Lake Street Capital Markets. Please state your question.
Great. Thanks for taking the questions. Was hoping to follow up on your comments, Bob, about some of the record pipeline that you're referencing. Curious if you can put any numbers around that, whether that be percent up year-over-year, quarter-over-quarter, number of units in backlog. Just help us understand just how significant that pipeline is right now and when that could start to convert. Thanks.
Yeah, sure. Our pipeline from Q1 of this year, it's grown close to fourfold, all right? Actually, it's more than doubled in the U.S. But what we had done is we did a real sanitation from the legacy team with respect to just some old deals and cleaned up a little bit of pipeline, put a little bit more rigor and definition into our pipeline. We had grown that, or so we had taken it down, and then we built it up a bit, but we've now more than doubled it since then. And so yeah, we're at a nice inflection point with respect to the growth there. Was there another part of that question?
Just thoughts around when that could start to translate to revenue.
Yeah. We're already starting to see that translation. In fact, we have the range for next year, as mentioned, for the $16 million-$18 million, and we have our range within Q1. Based off of some of the recent wins we have right now and as far as our pipeline build, we're really bullish around how these deals are going to be converting in the quarter we're in now and next quarter. We don't have those yet, and we can't obviously share. Yeah, our win rate is growing. It's increasing, and we're expecting to have that conversion reflected.
Yeah, it's a nice bump up because there's a couple of aspects or reasons for that, not just the increase in the pipeline, but the fact of the matter is there's less competitors in the field right now, so we're expecting, just based off of that, to have a higher win rate.
Got it. Very helpful. Was hoping to shift over to Gen 2. Once that is through the approval process, how should we think about what is required to get on formulary with the GPOs? I assume the Gen 1 doesn't suffice, and you'll have to do some sort of amendment to include the Gen 2, but maybe any clarifying commentary around that would be helpful. Thanks.
Yeah, that's just a quick update with the GPOs. They're really used to doing this, so it's really just an extension of what we have. It's nominal as far as time and effort, and then it's just a matter of. Really, that's it. It's a pretty simple process.
Okay, fair enough. Then just last one from me, and apologies in advance, this is splitting hairs a little bit. I think in the last conference call, the calendar Q2 conference call, we were talking a fair bit about the audit readiness process, and at least at that point in time, it seemed like it was kind of a near-term event, that that was going to be complete in a few months, and it feels like that maybe took a little bit longer than anticipated. Any additional color related to maybe what happened there and why that might have taken a little bit longer?
Yeah, it's not necessarily that it took longer. There's a lot of rigor that's involved with this. You have the installation qualification aspects of a build of a product to the operational qualifications, building up to the performance and the process readiness. We didn't underestimate anything. In fact, we, if anything, we knew where we'd be, and it would be in this part of the second half of the year, and we were expecting it to be right around where we're at now. But no, nothing was slowed down or anything like that. Everything actually was just. We did a lot of repeatability testing and a lot more stability testing. Wanted to make sure that all of our testing was tight. So no, nothing, no surprises, let's put it that way. Yeah.
Okay, great. Thanks for taking the questions.
Yeah. You got it.
Just a reminder to the audience, to ask a question, press star one on your phone. To remove yourself from the queue, press star two. Your next question comes from Mike King with Rodman & Renshaw. Please state your question.
Hey, guys. Thanks for taking the question. I also want to drill down a little bit more on this FDA review process, Bob. When we met with you and Dan a couple of weeks ago, we were discussing the necessity for FDA to get comfortable that the units could be used in ambulances and on helicopters and that kind of thing. I mean, is that still part of it, or is there something new that's arisen, or is this all part of the same process that you're going through with the auditing?
Yeah, nothing is new. That was part of our PMA supplement paperwork build as well as our testing, so we did a lot of testing on altitude testing. We worked all of that actually months ago. That was part of this process, and that has all been documented in part of our paperwork. That is actually all behind us, and this audit part is really just the back end of the high-level assembly assessments and audit. That is all done. We are completely done with that, and we are really happy with how that all worked out, so we are past all that.
Are there any personnel limitations or other aspects of the device division at FDA that are making turnaround times longer than you would anticipate?
I do not think so. What I do know is on the speed side, and something that is going to bode well for us, is that our R&D facility is an hour and a half away from our contract manufacturer. What ends up happening when you get into the audit phase, often, for a situation like this when you are dealing with a medical device, you could have a research and development division that is in California, but the contract manufacturer could be in Massachusetts, and then you have to deal with two different audit teams in order to manage that, or it could be an overseas and U.S. location, where ours are, we are an hour and a half away from each.
This is actually going to, if anything, speed up the audit process because it will be one team, and again, that day and a half process really is something that works well for us.
Okay. Then just real quick on the win rate side, can you just talk about what's responsible, what's driving that? Is it the GPO partnerships, the hospitals, a better understanding of the device? Maybe you can talk a little bit about the win rate.
Yeah. I mean, our technology has been really well received, and that's what it is. The ease of use with respect to our product is just really well received. So, our customers are really happy with that. They're really happy with how easy it is to use. That's helping us with win rates because as you start growing your customer base. Remember, we just started putting this product out a few years ago, the first-generation product. The first year, there was a few sites that were using the product, and now we have dozens and dozens of hospitals with that many more sites.
So, we have a couple hundred units that are out there that are being used, and we have so many more referenceable customers that are out there that are speaking on our behalf, and that's really helping because people are saying, "Hey, listen, it's not just that this is a real innovative product. It's actually really easy to use on top of being innovative." As you know, this is a drug that's being delivered through a medical device that we're creating out of thin air. Well, that's all well and good, but if you're not doing that easily for the customer, all that is a really kind of a catchy phrase, and we're able to kind of win on both ends there.
That reflects and goes right to the customer, and the customer sees that, and that's what's helping our win rates because as we're getting into conversations with hospital systems that might be across the city or across the state, or it might be a respiratory therapist that knows somebody in that hospital across the country, they're calling each other, and they're hearing really good things about us, and that's why we're winning. So, yeah, it's pretty good stuff.
Got you. Can you say, I do not know if revenue is still kind of small, so I do not know if it is really relevant right now, but can you say anything about your sort of average ticket size? Is your average sale increasing, or is it more unit volume that is driving the revenues? Thank you.
Yeah. It is these two things. It is the volume and it is the international business that is driving our revenue up right now. Our average deal size is about the same, and I could say roughly it is right around $250,000 is the average deal size when we have these deals anywhere from, whatever, $30,000 to north of $1 million, and can go way higher than that. We are working on a number of larger deals, but the net of it is our average deal size, about $250,000.
We do know when we have our next-generation product, we are going to be competing for much larger deals, which will definitely increase our overall deal size. Our average deal size will be bumping up, way up from the $250,000. Our international business is really helping as well as far as revenue because that is immediate recognized revenues. We get direct sales internationally.
We get direct sales also in the VA system, where we have had a couple of recent wins there as well, and that drops right to the revenue line there, different than, of course, as you know, the U.S. business, which is a subscription model. That is the net of it.
Thanks for taking the questions.
Yeah, you got it.
Thank you, and we have reached the end of the question and answer session. I will now turn the call over to Robert Goodman for closing remarks.
All right. I want to thank everybody for joining the call today, for all your support, and all your interest, and look forward to speaking with everybody next quarter. Have a great night. Thank you.
Thank you, all parties. You may now disconnect.